EUVIMEDAtrasti EUVIMED
Leserbrief

Letter: Circulating CD4 + PD ‐1 + T Cell Ratio Predicts Response to Pegylated Interferon‐Alpha Therapy in Chronic Hepatitis B

Yonghong Wang iD, Bei Cai, Chengrun Song, Jiangnan Peng, Taoyou Zhou iD, Jiajie Lu, Xuezhong Lei, Enqiang Chen

Alimentary Pharmacology & Therapeutics · 2026-07 · 64 (1) · 122-124

DOI: 10.1111/apt.70646 ↗

At a glance

Leserbrief in Alimentary Pharmacology & Therapeutics, published online on 2026-03-26. Written by Yonghong Wang and 7 co-authors. Institution: Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China. 1 references.

SantraukaBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Santrauka nepasiekiama.

Authors and institutions

  • Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.

ORCID profiles: Yonghong Wang, Taoyou Zhou

Cite

APA

Wang, Y., Cai, B., Song, C., Peng, J., Zhou, T., Lu, J., Lei, X., & Chen, E. (2026). Letter: Circulating CD4 + PD ‐1 + T Cell Ratio Predicts Response to Pegylated Interferon‐Alpha Therapy in Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics, 64(1), 122-124. https://doi.org/10.1111/apt.70646

Vancouver

Wang Y, Cai B, Song C, Peng J, Zhou T, Lu J, et al. Letter: Circulating CD4 + PD ‐1 + T Cell Ratio Predicts Response to Pegylated Interferon‐Alpha Therapy in Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics. 2026;64(1):122-124. doi:10.1111/apt.70646

BibTeX
@article{Wang2026,
  author = {Wang, Yonghong and Cai, Bei and Song, Chengrun and Peng, Jiangnan and Zhou, Taoyou and Lu, Jiajie and Lei, Xuezhong and Chen, Enqiang},
  title = {Letter: Circulating CD4 + PD ‐1 + T Cell Ratio Predicts Response to Pegylated Interferon‐Alpha Therapy in Chronic Hepatitis B},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {1},
  pages = {122--124},
  doi = {10.1111/apt.70646}
}
Start for free →